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Introduction
H
epatitis  B,  the  most  serious  type  of  viral 
hepatitis,  is  a  major  health  problem 
throughout  the  world.  According  to  a  WHO 
report, around 2 billion people are infected with 
the  hepatitis  B  virus  (HBV)  in  the  world,  and 
about 600,000 people die annually due to its acute 
or chronic consequences. There are more than 350 
million HBV carriers in the world (1). People who are 
in continuous contact with blood and bodily fluids 
are the most likely to contract hepatitis B. High-
risk populations include dialysis patients, health-
care workers, infants born to mothers infected with 
HBV, and intravenous drug abusers (2).
Vaccination against hepatitis B plays an important 
role in the prevention of HBV infection in high-risk 
population.  An  effective  vaccination  can  prevent 
HBV infection in 95% of immunized individuals as 
well as the hepatocellular carcinoma in the children 
of chronic HBV infection (3).
A predictable group for hepatitis B contamination 
as  high-risk  population  was  the  first  target  for 
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Background and Aims: Currently, vaccination is the most effective protective tool against hepatitis B virus infection. 
Some studies have shown that positive results for a hepatitis B virus surface antigen (HBsAg) test may be seen after 
vaccination. The aim of this study was to compare the incidence of positive HBsAg results after vaccination with two 
different hepatitis B recombinant vaccines.
Materials and Methods: In this clinical trial study, 62 healthy adult volunteers were randomly assigned to receive either 
the Engerix-B or the Hepavax-Gene hepatitis B recombinant vaccine. Blood samples were drawn 1, 3, and 5 days after 
vaccination and were tested for HBsAg using two different ELISA kits (Behring and Mega).
Results: HBsAg was positive in 5, 3, and 2 participants of the Engerix-B group in the 1st, 3rd, and 5th days after 
vaccination, respectively, using the Behring ELISA kit; the test was positive in only one subject in the Hepavax-Gene 
group, on the 5th day after vaccination. No positive result was seen in any groups when the Mega ELISA kit was used to 
test the specimens. 
Conclusions:  Our  results  showed  transient  HBsAg  antigenemia  after  vaccination  against  hepatitis  B.  This  condition 
depends on the type of vaccine and the HBsAg diagnostic test. 
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vaccination  in  the  United  States  after  the  first 
development of hepatitis vaccine in 1981. In contrast, 
the vaccine was not very successful and the rate of 
hepatitis B continued to grow. Therefore, in 1991 the 
Centers for Disease Control suggested vaccination 
for both high-risk adolescents and all newborns, and 
subsequently the international recommendation (by 
WHO) was to vaccinate all infants against hepatitis 
B by 1997 (4). This strategy led to a decrease in the 
incidence of hepatitis B worldwide (3, 5, 6).
Some  studies  have  reported  positive  results  of 
HBsAg  tests  after  hepatitis  B  immunization  in 
infants  (7-9) as well as adolescents  (5, 10, 11). False 
positive HBsAg results after vaccination can lead to 
the misdiagnosis of being infected with hepatitis B 
for healthy individuals, causing unnecessary concern 
and treatments. A careful diagnosis of HBV is even 
more important in blood donors. Dow et al.  (12) 
showed  that  hepatitis  B  vaccination  can  lead  to 
a misdiagnosis in blood donors in the week after 
vaccination. Otağ (11) Emphasizes that the period of 
antigenemia could extend for up to one month. The 
aim of this study was to compare the incidence of 
positive results of HBsAg tests after vaccination with 
two different hepatitis B recombinant vaccines.
Materials and Methods
This  clinical  trial  study  was  conducted  on  62 
healthy medical students who were at the beginning 
of their clinical courses and needed to be vaccinated 
against HBV. They were between 20 and 22 years 
old and tested negative for HBc antibody and had 
no history of HBV vaccination, jaundice, or blood or 
blood-derived-products transfusion during the past 
3 months. The study protocol was approved by the 
research ethics committee of the Birjand University 
of Medical Sciences, and all participants signed an 
informed-consent  form  for  participation.  Subjects 
were assigned into two vaccination groups by simple 
randomization.  The  two  types  of  vaccines  were 
Hepavax-Gene (manufactured by Green Cross Vaccine 
Corp., Seoul, Korea) and Engerix-B (manufactured 
by  GlaxoSmithKline,  Rixensart,  Belgium).  There 
were 32 and 30 subjects in the Hepavax-Gene and 
Engerix-B groups, respectively. A full dose of vaccine 
was administrated intramuscularly for all subjects as 
the first dose of vaccination against HBV. All subjects   
were  vaccinated  1  and  6  months  after  the  first 
vaccination. Blood samples were drawn 1, 3, and 
5 days after the first dose of vaccination and tested 
for HBsAg by two different ELISA kits (Behring, 
Marburg,  Germany;  and  Mega,  Los  Angeles, 
California, USA). All tests were performed by one 
person in the same setting. The immunization status 
of  all  participants  was  evaluated  3  months  after 
vaccination  by  testing  for  HBsAb  using  Behring 
(Marburg,  Germany)  anti-HBs  ELISA  kits.  The 
results are expressed as mean ± standard deviation 
(SD) for quantitative variables and percentages for 
categorical  variables.  Categorical  variables  were 
compared with a Fisher exact test. P values of 0.05 
or less were considered statistically significant. All 
statistical  analyses  were  performed  using  SPSS 
version 15. 
Results
Of the 62 participants, 36 (58.1%) were female. 
Half  of  the  women  were  in  the  Engerix-B  group 
and half were in the Hepavax-Gene group. Positive 
results for the HBsAg test in the 1st, 3rd, and 5th 
day after vaccination with the two types of vaccines 
were  different  when  the  Behring  ELISA  kit  was 
used. In the Engerix-B group, 5 (16.7%), 3 (10%), 
and 2 (6.7%) people had positive results 1, 3, and 
5  days  after  vaccination,  respectively  (Table  1). 
In  the  Hepavax-Gene  group,  no  one  had  positive 
results in Days 1 and 3, and only 1 (3.1%) person 
tested positive 5 days after vaccination. There was a 
statistically significant differences between the two 
vaccination groups in the prevalence of false positive 
results of HBsAg on day 1 (Table 2).
No positive results were observed in any person in 
either vaccination group when the Mega ELISA kit 
was used to test for HBsAg in the blood specimens. 
All  subjects  were  tested  for  HBsAb  3  months 
after completing their vaccination. Additionally, all 
individuals in both groups had a protective antibody 
level of more than 10 IU/ml. 
Discussion
HBsAg is the most common serological marker 
for  the  diagnosis  of  hepatitis  B.  Contrary  to 
recent  studies  (11,  12),  primary  research  after  the 
development  of  plasma-derived  HBV  vaccine  did 
not  reveal  postvaccination  HBs  antigenemia  (13). 
Our study showed transient HBs antigenemia after 
administration  of  vaccinating  against  hepatitis  B. 
The  results  of  this  study  showed  that  different 
types of hepatitis B vaccines can result in different 
rates of false positive results for an HBsAg test. As 
shown in table 1, in the Engerix-B group, 8 (26%) 
people tested positive for HBsAg during 5 days after 
vaccination, but Hepavax-Gene caused antigenemia 
in only 1 subject (3.1%). In a similar study, Otag (11) 
found different rates of HBs antigenemia caused by Hepat Mon. 2010; 10(4): 298-301
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days after vaccination, respectively. There was one 
positive  antigenemia  in  the  Hepavax-Gene  group, 
which  was  found  on  Day  5.  Some  studies  have 
reported different times for the onset of antigenemia 
(14). Based on the results, all subjects with an onset 
of antigenemia in the first 3 days after vaccination 
had a negative HBsAg result on Day 5. The clearance 
period  (i.e.,  the  time  between  the  appearance  of 
HBsAg and when it is undetectable) in our study 
ranged  between  2  and  4  days.  In  Otag’s  study, 
antigenemia disappeared within 3 days  (11). Some 
studies  have  reported  prolonged  antigenemia  in 
neonates or hemodialysis patients, even after several 
weeks (9, 15). In our study, there was no difference in 
the acquisition of immunity between the Engerix-B and 
Hepavax-Gene groups after 3 months of follow-up. 
Conclusion
Our  results  indicate  that  HBs  antigenemia 
may  occur  after  vaccination  against  hepatitis  B. 
This  positive  HBsAg  result  can  vary  by  the  type 
of  vaccine  or  across  different  HBsAg  ELISA  kits. 
Therefore, health-care workers should be informed 
about  possible  HBs  antigenemia  after  vaccination 
against hepatitis B. Still, there is no difference in 
immunization  between  subjects  with  and  without 
false positive HBsAg results.
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